Press Releases from Charles River
   
 
 
   
   
 

Charles River Announces Second-Quarter 2009 Results

Downloadable version.

  • Sales Decrease 12.5% to $308 Million
  • GAAP Earnings per Share of $0.52 and Non-GAAP Earnings per Share of $0.66
  • Updates Sales and EPS Guidance for 2009
  • Expands Opportunities Through Strategic Acquisitions and Partnership

WILMINGTON, Mass.--(BUSINESS WIRE)--August 4, 2009--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2009. For the quarter, net sales decreased 12.5% to $308.2 million from $352.1 million in the second quarter of 2008. Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting in part the negative impact of foreign exchange, as well as softer market demand for the Company’s broad portfolio of products and services, as pharmaceutical and biotechnology clients reprioritize their drug development pipelines and restructure their operations. Foreign currency translation reduced net sales by 5.1%.

Click here to read the full release.

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Jan 23 - Introducing Eureka
Dec 12 - ‘Tis the Season for Giving
Feb 27-Mar 02 - San Diego, CA - Biopharmaceutical Development and Production Week
Feb 17-Feb 18 - Aichi, Japan - Japan Society of Experimental Diabetes and Obesity (JSED...
Mar 06-Mar 06 - Seattle, WA - Charles River LAL Seminar Series
Feb 08-Feb 10 - Brussels, Belgium - 6th Charles River European Short Course on Laborato...
view all
Manager International Tax Wilmington, MA
Scientist I Wilmington, MA

Charles River Laboratories, Inc.